UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): October 24, 2001
OXIGENE, INC.
(Exact name of registrant as specified in its charter)
Delaware 0-21990 13-3679168
--------------- ------------- --------------------
(State or other (Commission (IRS Employer
jurisdiction of File Number) Identification No.)
incorporation)
321 Arsenal Street
------------------
Watertown, Massachusetts 02472
---------------------------------------------------
(Address of principal executive offices) (Zip Code)
Registrant's telephone number, including area code: (617) 673-7800
-1-
Item 5. Other Events and Regulation FD Disclosure.
On October 24, 2001, the Registrant issued a press release, a copy of which is
attached hereto as Exhibit 99.1, announcing that it has regained full
development and licensing rights to its Combretastatin family of vascular
targeting agents, following a decision by the Registrant and Bristol-Myers
Squibb to conclude their research collaboration and licensing agreement. The
Registrant also announced that it would end further clinical development of its
benzamide-based product, Declopramide, to focus its resources exclusively on
vascular targeting.
Item 7. Financial Statements and Exhibits.
(c) The following exhibits are filed with this report:
Exhibit Number Description
-------------- -----------
99.1 Press release of Registrant dated October 24, 2001.
99.2 Transcript of conference call conducted by Registrant on
October 25, 2001.
Item 9. Regulation FD Disclosure.
On October 25, 2001, the Registrant held a conference call (the "Conference
Call") to discuss Third Quarter results and to comment on the acquisition of the
full development and licensing rights to its Combretastatin family of vascular
targeting agents following the conclusion of the research collaboration and
licensing agreement with Bristol-Myers Squibb. A transcript of the Conference
Call is attached hereto as Exhibit 99.2.
-2-
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the
Registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
OXIGNENE, INC.
(Registrant)
Date: October 29, 2001 By: /s/ Frederick Driscoll
-----------------------
Name: Frederick Driscoll
Title: President of Operations and Finance
-3-
EXHIBIT INDEX
Exhibit Number Description
-------------- -----------
99.1 Press release of Registrant dated October 24, 2001.
99.2 Transcript of conference call conducted by Registrant on
October 25, 2001.
-4-